Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy. By using in vitro, ex vivo and in vivo approaches, we have identified here that lipid rafts constitute a new target in MM. We have found that the phospholipid ether edelfosine targets and accumulates in MM cell membrane rafts, inducing apoptosis through co-clustering of rafts and death receptors. Raft disruption by cholesterol depletion inhibited drug uptake by tumor cells as well as cell killing. Cholesterol replenishment restored MM cell ability to take up edelfosine and to undergo drug-induced apoptosis. Ceramide addition displaced cholesterol from rafts, and inhibited edelfosineinduced apoptosis. In an MM animal model, edelfosine oral administration showed a potent in vivo antimyeloma activity, and the drug accumulated preferentially and dramatically in the tumor. A decrease in tumor cell cholesterol, a major raft component, inhibited the in vivo antimyeloma action of edelfosine and reduced drug uptake by the tumor. The results reported here provide the proofof-principle and rationale for further clinical evaluation of edelfosine and for this raft-targeted therapy to improve patient outcome in MM. Our data reveal cholesterolcontaining lipid rafts as a novel and efficient therapeutic target in MM, opening a new avenue in cancer treatment.
Introduction
Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a promising family of anticancer drugs that act at the membrane level (Gajate and Mollinedo, 2002; Mollinedo et al., 2004; Mollinedo, 2007) . The ALP prototype edelfosine (1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine, ET-18-OCH 3 ) induces apoptosis in tumor cells (Mollinedo et al., 1997) through co-capping of the Fas/CD95 death receptor with membrane rafts (Gajate et al., 2000a Mollinedo, 2001, 2007) . In vitro studies have shown that this phospholipid ether is preferentially taken up by tumor cells, leading to the intracellular activation of the Fas/CD95 death receptor, independently of its ligand FasL/CD95L (Mollinedo et al., 1997; Gajate et al., 2000a Gajate et al., , 2004 Gajate and Mollinedo, 2001 ). Edelfosine-induced apoptosis is mediated by the recruitment of Fas/CD95 and downstream signaling molecules into membrane rafts Mollinedo, 2001, 2007; Gajate et al., 2004) . Lipid rafts are membrane microdomains highly enriched in cholesterol and sphingolipids, and the proteins located in these microdomains are limited in their ability to freely diffuse over the plasma membrane, affecting protein function (Simons and Toomre, 2000) . Recent evidence suggests that membrane rafts constitute the linchpin from which Fas/CD95 signaling is launched (Gajate et al., , 2009a Mollinedo, 2005, 2007) .
Multiple myeloma (MM) is the second most prevalent blood cancer, accounting for 10% of all hematological malignancies (Hussein et al., 2002) . MM is characterized by the accumulation of malignant plasma cells in the bone marrow with frequent occurrence of lytic bone disease. Although therapeutic advances in the treatment of MM have improved remission duration and overall survival, relapse of the disease is inevitable for nearly all patients, and MM remains a deadly B-cell malignancy (Mihelic et al., 2007) . Therefore, development of novel therapeutic strategies is urgently needed to improve survival in MM patients. MM cells show a relatively low proliferative index and a poor apoptotic rate (Dimberg et al., 2005) , and hence it is likely that the transforming event is a failure in death regulation rather than a loss of growth control. This implies that a therapeutic potential for MM may lie in potentiating apoptosis, and thereby we hypothesized that MM might be suitable for the particular proapoptotic features of edelfosine.
Our previous in vitro data indicated that edelfosineinduced apoptosis in cancer cells, including MM, was mediated by the reorganization of raft protein composition Mollinedo, 2001, 2007; Gajate et al., 2004 Gajate et al., , 2009a , but here we studied whether edelfosine was acting by directly targeting rafts both in vitro and in vivo, using a clinically relevant disease. By using in vitro, ex vivo and in vivo approaches, we show here that edelfosine targets tumor cell lipid rafts and accumulates in these membrane domains, inducing selective apoptosis in MM cells through its preferential uptake in tumor cell rafts. Our data set raft-targeted therapy as a new framework in MM treatment, and identified edelfosine as the first raft-targeted antitumor drug, thus opening a new avenue in cancer chemotherapy.
Results
Edelfosine induces Fas/CD95-membrane raft co-clustering and selective killing in MM patientderived cells, sparing normal cells We have previously reported that edelfosine induced apoptosis in human MM cell lines, mediated by coclustering of the Fas/CD95 death receptor in lipid rafts (Gajate and Mollinedo, 2007) . Here, we found that edelfosine also induced apoptosis and co-aggregation of Fas/CD95 and rafts in CD138 þ malignant cells derived from MM patients (Figures 1a and b) , whereas CD138 À normal cells from the same patients, and human normal resting peripheral blood lymphocytes (PBLs), isolated from healthy volunteers, were spared ( Figure 1a) . MM patient-derived cells took up significant amounts of edelfosine (392±43 pmol per 10 6 cells after 1 h of incubation with 10 nmol [ 3 H]edelfosine; n ¼ 5), whereas CD138 À normal cells from the same patients and normal PBLs did not incorporate the drug (o20 pmol per 10 6 cells after 1 h of incubation with 10 nmol [ 3 H]edelfosine; n ¼ 3). In addition, normal human cells with distinct proliferation rates, such as purified B cells, human umbilical vein endothelial cells, hepatocytes, CD34 þ hematopoietic progenitor cells and adipose-derived stem cells, were resistant to edelfosine (o3% apoptosis following treatment with 10 or 20 mM edelfosine for 24 h, n ¼ 3) and did not incorporate significant amounts of drug (o20 pmol per 10 6 cells after 1 h of incubation with 10 nmol [ 3 H]edelfosine; n ¼ 3). By using the raft marker fluorescein isothiocyanate (FITC)-labeled cholera toxin (CTx) B subunit that binds to ganglioside G M1 (Schon and Freire, 1989) , mainly found in rafts (Harder et al., 1998) , we observed that 10 mM edelfosine promoted a potent co-aggregation of Fas/CD95 and rafts in malignant cells derived from MM patients (Figure 1b) . However, no co-clustering of Fas/CD95 and rafts was detected in normal CD138 À cells, resting PBLs or purified B cells following incubation with the phospholipid ether (data not shown). Furthermore, incubation of MM patient-derived cells with the cholesterol-depleting agent MCD (Christian et al., 1997) disrupted rafts (Gajate and Mollinedo, 2001) , as well as inhibited clustering of Fas/CD95 (data not shown) and apoptosis (41 ± 5 vs 12 ± 3 apoptosis in cells untreated vs pretreated with MCD, and then incubated with 10 mM edelfosine for 24 h; n ¼ 3). Thus, the patient-derived MM cells behaved similarly to MM cell lines (Gajate and Mollinedo, 2007) in their capacity to undergo co-clustering of Fas/CD95 rafts as the initial trigger for apoptosis (Mollinedo and Gajate, 2006b; Mollinedo, 2008) on edelfosine treatment. These data suggest that edelfosine shows a remarkable selectivity for primary tumor cells and cancer cell lines in its capacity to promote co-aggregation of Fas/CD95 and rafts and to induce apoptosis.
Accumulation of edelfosine in lipid raft clusters enriched in death receptors is critical for MM cell killing We next asked whether edelfosine interacted with MM cell membrane rafts. We tested this directly by Quesada et al., 2004; Nieto-Miguel et al., 2006) accumulated in well-defined patches that colocalized with raft clusters enriched in Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, death receptor (DR) 4 and DR5 (Figure 2b ). PTEedelfosine induced apoptosis in MM144 cells (38.6 ± 4.1 and 59.8±5.2% apoptosis following 24-h incubation with 10 and 20 mM PTE-edelfosine, respectively; n ¼ 3) at a similar concentration range as the parent drug edelfosine (51.9 ± 4.3 and 65.6 ± 6.4% apoptosis following 24-h incubation with 10 and 20 mM edelfosine, respectively; n ¼ 3), while sparing normal resting PBLs (o3% apoptosis following 24-h incubation with 10 or 20 mM PTE-edelfosine). Fluorescent PTE-edelfosine incorporation into the MM cell was blocked by addition of the parent drug (data not shown), indicating the specificity in the uptake, and PTE-edelfosine behaves as a bona fide analog to analyze edelfosine localization in the cell. Raft disruption by MCD treatment (Christian et al., 1997) inhibited edelfosine-induced apoptosis ( Figure 2c ) and clustering of Fas/CD95 and TRAIL receptors (data not shown) in MM144 cells. Similar results were obtained with the MM cell line MM1S (data not shown). These results indicate that edelfosine binds to rafts forming aggregates of edelfosine-rich rafts that recruit death receptors and convey apoptotic signaling.
Cholesterol is required for edelfosine uptake and drug-induced apoptosis We found that MM1S and MM144 cells took up edelfosine in the range 415-482 pmol per 10 6 cells after 1 h of incubation with 10 nmol [ 3 H]edelfosine. To assess the role of cholesterol, a critical raft component, in mediating drug uptake and edelfosine-induced apoptosis, we treated MM cell lines with the cholesterol-depleting agent MCD (Christian et al., 1997 ).
Measurements of [
3 H]cholesterol levels in cells that had been pre-equilibrated with this lipid showed that treatment with 2.5 mg/ml MCD for 30 min removed >67% of the cell cholesterol, in agreement with previous estimates (Barnes et al., 2004; Gajate et al., 2009b) . Disruption of lipid rafts by MCD inhibited both drug uptake ( Figure 3a ) and edelfosine-induced apoptosis MM144 cells were incubated with 10 mM PTE-edelfosine (PTE-EDLF) (blue fluorescence) for 15 h, washed with PBS-2% BSA, and then its colocalization with membrane rafts and death receptors Fas/CD95, DR4 and DR5 was examined using the FITC-CTx B subunit (green fluorescence for rafts) and specific antibodies against the distinct death receptors, followed by CY3-conjugated antibodies (red fluorescence for death receptors). Differential interference contrast (DIC) images are also shown. Bar, 6 mm. (c) MM144 cells were untreated (control), treated with 10 mM edelfosine for 24 h (EDLF), or pretreated with 2.5 mg/ml MCD for 30 min and then incubated for 24 h in culture medium in the absence (MCD) or presence of 10 mM edelfosine (MCD þ EDLF), and apoptosis was analyzed by flow cytometry. The percentage of apoptotic cells, assessed by a DNA content less than G 1 (sub-G 1 ), is shown in parentheses in each histogram. The position of the G 1 peak is indicated by arrows. Data shown are representative of three separate experiments.
Lipid raft-targeted therapy in multiple myeloma F Mollinedo et al ( Figure 3b ). Replenishment of cholesterol cell content by exposure of MCD-treated cells to 100 mg/ml cholesterol for 1 h led to the recovery of B109% cell cholesterol, thus reconstituting cellular cholesterol levels, and cells regained the capacity to take up edelfosine and underwent apoptosis following edelfosine treatment ( Figures  3a and b) . These results indicate that the presence of cholesterol in rafts is essential for the uptake and apoptotic action of edelfosine.
Ceramide inhibits edelfosine-induced apoptosis N-octanoyl-sphingosine (C 8 -ceramide) is a cell-permeable analog of naturally occurring ceramides that closely mimics the effects of physiological long-chain ceramide (Karasavvas et al., 1996) . Previous reports have shown that both natural and synthetic ceramides specifically displace sterols from lipid rafts affecting their properties and molecular composition (Megha and London, 2004) . In this regard, cholesterol is replaced by ceramide in cholesterol-containing rafts to form ceramide-rich rafts (Megha and London, 2004) . C 8 -ceramide has been reported to displace cholesterol from raft domains and destabilize them (Nybond et al., 2005; RouquetteJazdanian et al., 2007) . We found that the pretreatment of MM1S cells with C 8 -ceramide removed cholesterol from the rafts (31±5 vs 9±2 mg cholesterol per mg protein in untreated vs C 8 -ceramide-treated cells; n ¼ 3), and inhibited both edelfosine uptake ( Figure 4a ) and edelfosine-induced apoptosis (Figure 4b ). These results are in agreement with a critical requirement of cholesterol in rafts for the uptake of edelfosine into MM cells and the subsequent drug-induced apoptotic response.
Edelfosine accumulates in MM tumor and inhibits human MM cell growth in vivo We next determined the in vivo antimyeloma activity of edelfosine using a severe combined immune deficiency (SCID) mouse plasmacytoma model. Following toxicity analyses (data not shown), we found that a daily oral administration dose of 30 mg/kg edelfosine was well tolerated, 45 mg/kg being the maximum tolerated dose. CB17-SCID mice were inoculated with 3 Â 10 7 MM1S cells in 100 ml phosphate-buffered saline (PBS), together with 100 ml Matrigel. On the development of a palpable tumor, mice were randomized into drug-treated Lipid raft-targeted therapy in multiple myeloma F Mollinedo et al (30 mg/kg edelfosine, daily oral administration for 29 days) and control (water vehicle) groups of 12 mice each. Serial caliper measurements were made to determine the rate at which the tumor grew (Figure 5a) . A comparison of tumors isolated from nontreated control and drugtreated MM-bearing mice, at the end of the 1-month treatment, rendered a remarkable and statistically significant (Po0.01) antimyeloma activity of edelfosine, with a reduction of B88% in tumor weight and volume, and four tumor-free mice (Figures 5b and c) . Organ examination at necropsy did not reveal any apparent toxicity (data not shown). Compared with the large, highly vascularized tumors from drug-free mice, the small tumors from edelfosine-treated mice were pale and poorly vascularized (Figure 5b) . No significant differences in mean body weight were observed between drug-treated and drug-free control animals (3-5% of body weight loss in the treated group vs control group). At the end of the in vivo assay, we found a mean concentration of edelfosine in plasma of 5.42 ± 0.49 mg/ml (n ¼ 12), using high-performance liquid chromatography-mass spectrometry (HPLC-MS) analysis. Interestingly, edelfosine was remarkably more concentrated in the MM tumor (136.83 ± 18.41 mg/g, n ¼ 8) than in the liver (7.91 ± 1.04 mg/g, n ¼ 8) and kidney (13.46±0.26 mg/g, n ¼ 8). Tumor/plasma concentration ratio of edelfosine was dramatically higher than that detected in both kidney and liver, organs that are directly implicated in drug excretion (Figure 5d ). Thus, our drug biodistribution studies indicate a rather selective accumulation of edelfosine in the MM tumor in vivo.
Tumor cholesterol levels affect edelfosine antimyeloma activity in vivo To analyze the putative role of rafts in edelfosine action in vivo, the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin was given to mice (1.5 mg/kg) to reduce cholesterol levels. An in vivo MM-bearing CB17-SCID mouse model assay was conducted involving four groups: untreated control mice, pravastatin-treated mice, edelfosine-treated mice, and mice treated with pravastatin and edelfosine. Pravastatin has been reported to reduce de novo cholesterol synthesis in the liver and in a number of tissues (Koga et al., 1990; Elahi et al., 2008) . MM tumors derived from pravastatintreated mice contained a lower content of cholesterol than tumors isolated from untreated mice, 6.9 vs 13.4 mg cholesterol per g of tumor, respectively. Pravastatin significantly inhibited the in vivo antitumor action of edelfosine (Figures 6a, c and d) and drastically decreased the tumor/plasma concentration ratio of edelfosine (Figure 6b ). This suggests that tumor cholesterol content has a major role in edelfosine uptake and in the antimyeloma activity of edelfosine in vivo.
Although statins are lipid-lowering drugs that block cholesterol biosynthesis, they exert a wide array of effects by inhibiting prenylation of proteins involved in signal transduction (Perez-Sala and Mollinedo, 1994; Perez-Sala et al., 1995; Auer et al., 2002; Jasinska et al., 2007) . On these grounds, we cannot rule out the possibility that the above effect of pravastatin could be due, at least in part, to prenylation inhibition. Lipid raft-targeted therapy in multiple myeloma F Mollinedo et al
Discussion
The in vitro and in vivo data reported here identify lipid rafts as a novel and effective therapeutic target in MM, setting a novel framework in cancer chemotherapy. Our results show edelfosine as the first raft-targeted drug, accumulating in lipid rafts and triggering the demise of MM cells. Hence, edelfosine can be considered as the paradigm of this new raft-targeted therapy. The accumulation of edelfosine in rafts might be explained by its high affinity for cholesterol (Ausili et al., 2008; Busto et al., 2008) , because of geometry compensation of the 'cone shape' of sterols and the 'inverted cone shape' of edelfosine that leads to a stable bilayer (Busto et al., 2008) . Edelfosine targets membrane rafts of malignant cells, inducing raft aggregates that act as scaffolds for the recruitment and concentration of Fas/ CD95 and TRAIL receptors. Previous reports have shown that MM cells express Fas/CD95, but are rather resistant to undergo apoptosis in response to the external stimulation of Fas/CD95 by agonistic antiFas/CD95 antibodies (Dimberg et al., 2005) . However, edelfosine activates Fas/CD95 and induces its aggregation in rafts from within the cell independently of its ligand , triggering subsequently downstream extrinsic and intrinsic signaling pathways that eventually lead to apoptosis (Gajate et al., 2000a (Gajate et al., , b, 2004 (Gajate et al., , 2009a Mollinedo, 2001, 2007) .
The results reported here, together with our previous findings (Gajate and Mollinedo, 2007; Gajate et al., 2009b) , suggest the following cascade of events in edelfosine-induced apoptosis in MM cells: drug accumulation in lipid raft -raft reorganizationFas/CD95 activation -DISC -mitochondrial cytochrome c release -apoptosome. The initial accumulation of edelfosine in lipid rafts is critical to trigger the whole apoptotic pathway, and raft disruption prevents edelfosine uptake and the subsequent activation of both extrinsic and intrinsic pathways (Gajate and Mollinedo, 2007; Gajate et al., 2009b) .
Although there is increasing evidence that Fas/CD95 apoptotic signaling is initiated through the recruitment of Fas/CD95 receptor in lipid rafts (Mollinedo and Gajate, 2006a, b; Mollinedo, 2001, 2007; Mollinedo, 2008) , it is not clear whether these domains, initially enriched in cholesterol, must turn into ceramide-rich rafts to deliver apoptotic signals (Grassme et al., 2003) . In this regard, edelfosine does not activate sphingomyelinase and no ceramide is generated on its action , suggesting that edelfosine acts through cholesterol-rich rafts. As a matter of fact, we found here that the presence of ceramide, which is known to displace cholesterol from lipid rafts (Megha and London, 2004) , removes cholesterol from MM cell lipid rafts and inhibits both edelfosine uptake and edelfosine-induced apoptosis. On these grounds, we Figure 6 Pravastatin inhibits the in vivo antitumor action of edelfosine. MM1S-bearing CB17-SCID mice were randomly assigned to four cohorts of eight mice, each receiving a daily oral administration of water vehicle (control), 30 mg/kg edelfosine (EDLF), 1.5 mg/kg pravastatin and pravastatin þ EDLF for 29 days. Tumor shortest and longest diameters were measured weekly to calculate the apparent tumor volume in the above four experimental groups (a). Data shown in panel a are means ± s.e. of eight mice in each group. (b) Tissue/plasma concentration ratios, in the liver, kidney and tumor, of edelfosine content after daily oral administration of edelfosine (EDLF) and pravastatin þ EDLF for 1 month in MM-bearing SCID mice (means ± s.e., n ¼ 5). **Indicate that the tumor/ plasma ratio values in EDLF and pravastatin þ EDLF are significantly different at Po0.01. Mice were killed 30 days after the initiation of drug treatment, and tumor weight (c) and volume (d) were measured, showing that pravastatin hampered the antitumor effect of edelfosine. *Denotes values that are significantly different between the indicated groups at Po0.05.
Lipid raft-targeted therapy in multiple myeloma F Mollinedo et al conclude that the lipid rafts involved in both the uptake and apoptotic action of edelfosine are cholesterol-rich rafts and not ceramide-rich rafts.
Our biodistribution data in the MM murine model showed a mean concentration of edelfosine in plasma of 5.42 mg/ml (10.35 mM; edelfosine molecular mass, 523.7). Thus, the in vitro effects reported herein, rendered by 10 mM edelfosine, were detected at a pharmacologically relevant concentration. The edelfosine-induced death receptor concentration in specific domains of the cell surface reported here has interesting clinical consequences, as it might either induce apoptosis by itself, through subsequent recruitment of downstream signaling molecules (Gajate and Mollinedo, 2001 , 2007 Gajate et al., 2004 Gajate et al., , 2009a Mollinedo and Gajate, 2006a, b) , or sensitize cancer cells to death receptor ligands, including TRAIL (Gajate and Mollinedo, 2007) , currently under clinical trials.
Using an MM xenograft mouse model, we have found that edelfosine accumulates in high amounts in the tumor, highlighting the rather selective affinity of edelfosine for tumor cells. In addition, edelfosine shows a remarkable in vivo antimyeloma activity, leading to drastic tumor regression. Following edelfosine oral administration in nontumor-bearing SCID mice, we have found a rather wide drug distribution pattern to several tissues, including the lung, spleen, intestine, liver and kidney (de Mendoza et al., 2009) . Interestingly, we found here that when SCID mice contained MM tumors, edelfosine distribution was dramatically shifted toward the tumor (tumor/plasma concentration ratio D20), indicating a rather selective tumor targeting for edelfosine. We did not find any apparent damage in the distinct organs analyzed following necropsy in the in vivo studies reported here, and have recently found that edelfosine lacked toxicity in rats using histological, functional and biochemical parameters . Furthermore, the small tumors isolated from edelfosine-treated mice were pale and poorly vascularized. This might be in agreement with reports showing an antiangiogenic effect of edelfosine (Zerp et al., 2008) .
Interestingly, pharmacological inhibition of endogenous cholesterol synthesis, which diminishes the cholesterol content of membrane rafts (Zhuang et al., 2005) , led to a reduction in tumor cholesterol content as well as to a significant decrease in edelfosine antitumor activity and drug accumulation in the tumor. A decrease in cholesterol level might affect lipid rafts, thus hampering edelfosine uptake. Indeed, cholesterol depletion in MM cells inhibited both edelfosine uptake and drug-induced apoptosis. However, cholesterol repletion restored the ability of tumor cells to take up edelfosine and to undergo edelfosine-induced apoptosis. These cholesterol depletion/replenishment assays show that lipid rafts are critical for the uptake of edelfosine and for the triggering of apoptosis by this drug. The finding that edelfosine binds to cholesterol-containing rafts is of particular importance as the cholesterol content in tumor cells has been shown to be higher than in normal cells (Dessi et al., 1994; Kolanjiappan et al., 2003; Freeman and Solomon, 2004; Tosi and Tugnoli, 2005) . Furthermore, cancer cells have been reported to display higher levels of cholesterol-rich lipid rafts than their normal counterparts (Li et al., 2006) . Edelfosine shows a high affinity for cholesterol, and for cholesterol-enriched membranes such as rafts (Ausili et al., 2008; Busto et al., 2008) , because of the complementarity of the molecular geometrics of sterols and edelfosine (Busto et al., 2008) , and this feature may have interesting biomedical applications. The high cholesterol content in tumor cells, together with the avidity for cholesterol of edelfosine, might contribute in part to the accumulation of edelfosine in tumor cells. Nevertheless, the uptake of edelfosine by tumor cells has been suggested to be mediated by a putative protein transporter that remains to be identified (Mollinedo et al., 1997; Hanson et al., 2003) . It might be envisaged that tumor cells could undergo a series of changes in lipids, including cholesterol, and proteins, including transporters, which might putatively affect raft organization in a way that facilitates edelfosine uptake.
The results reported here provide the proof-ofprinciple and rationale for further clinical evaluation of edelfosine and for this new raft-targeted therapy to improve patient outcome in MM.
Materials and methods

Cell lines and primary cells
Detailed information on the MM cell lines, primary tumor cells, and normal primary cells used in this study is included in the Supplementary data.
Apoptosis assay
Quantitation of apoptotic cells was determined by flow cytometry as the percentage of cells in the sub-G 1 region (hypodiploidy) in cell-cycle analysis as previously described (Gajate et al., 2000b) . Edelfosine was from INKEYSA (Barcelona, Spain) and APOINTECH (Salamanca, Spain).
Confocal microscopy
Cells were settled onto poly-L-lysine-coated slides and analyzed with a Zeiss LSM 510 laser scan confocal microscope (Oberkochen, Germany) for membrane raft and Fas/CD95 visualization, using FITC-CTx B subunit (Sigma Chemical, St Louis, MO, USA) and anti-human Fas/CD95 SM1/1 IgG 2a mouse monoclonal antibody (Bender Medsystems, Vienna, Austria) followed by CY3-conjugated antimouse antibody (Pharmacia, Uppsala, Sweden) as described in Gajate and Mollinedo (2001) . Colocalization assays were analyzed by excitation of both fluorochromes in the same section. Negative controls, lacking the primary antibody or using an irrelevant antibody, showed no staining.
Edelfosine localization by fluorescence microscopy Cells were treated for 15 h with 10 mM fluorescent analog PTEedelfosine, provided by AU Acun˜a and F Amat-Guerri (Consejo Superior de Investigaciones Cientı´ficas, Madrid, Spain), and then incubated with the raft marker FITC-CTx B subunit to label lipid rafts, and with an anti-Fas/CD95 SM1/ 1 monoclonal antibody (Bender Medsystems) or specific monoclonal antibodies against the extracellular domains of DR4 and DR5 (R&D Systems, Minneapolis, MN, USA), followed by the corresponding CY3-conjugated secondary antibodies as previously described Gajate and Mollinedo, 2007) . Colocalization of the distinct fluorochromes was analyzed using a fluorescence microscope (Axioplan 2; Carl Zeiss MicroImaging) and a digital camera (ORCA-ER-1394; Hamamatsu, Shizuoka, Japan). Negative controls, lacking the primary antibody or using an irrelevant antibody, showed no staining.
Edelfosine uptake Drug uptake was measured as previously described (Mollinedo et al., 1997) after incubating 10 6 cells with 10 nmol [ 3 H]edelfosine for 1 h in RPMI-1640/10% heat-inactivated fetal bovine serum, and subsequent exhaustive washing (six times) with PBS þ 2% bovine serum albumin to remove the ether lipid loosely bound to the cell surface.
Lipid raft isolation
Lipid rafts were isolated by using lysis conditions and centrifugation on discontinuous sucrose gradients as previously reported (Gajate and Mollinedo, 2001 ). The location of G M1 -containing lipid rafts was determined by western blotting using CTx B subunit conjugated to horseradish peroxidase as previously described (Cheng et al., 1999) .
Cholesterol depletion and repletion
To deplete cholesterol, 2.5-3 Â 10 5 cells per ml were pretreated with 2.5 mg/ml MCD (Sigma) for 30 min at 37 1C in serum-free medium. Cells were then washed three times and resuspended in complete culture medium before the addition of edelfosine. For measurement of relative cholesterol contents, cells were preincubated at 37 1C for 14 h with 0.5 mCi/ml [ 3 H]cholesterol (Perkin Elmer NEN Dupont, Boston, MA, USA) in cellculture medium (Barnes et al., 2004; Gajate et al., 2009b) . After incubation without or with MCD, cells were washed, lysed and the radioactivity present in the lysates was then quantified by liquid-scintillation counting. For cholesterol repletion, 100 mg/ml of cholesterol balanced with MCD (watersoluble cholesterol; Sigma) was added for 1 h, and then the cells were washed and resuspended in culture medium for drug treatment. Cholesterol concentration was determined in cells and isolated membrane rafts as previously described (Hope and Pike, 1996; Zhuang et al., 2005) , following lipid extraction with chloroform/methanol/HCl, using the Infinity reagent (Thermo Scientific, Worthing, UK).
Xenograft mouse models CB17-SCID mice (Charles River Laboratories, Lyon, France), kept and handled according to institutional guidelines, complying with Spanish legislation under a 12/12 h light/dark cycle at a temperature of 22 1C, received a standard diet and acidified water ad libitum. CB17-SCID mice were inoculated subcutaneously into their lower dorsum with 3 Â 10 7 MM1S cells in 100 ml PBS and 100 ml Matrigel basement membrane matrix (Becton Dickinson). When tumors were palpable, mice were randomly assigned to cohorts of 12 mice each, receiving a daily oral administration of edelfosine (30 mg/kg) or an equal volume of vehicle (water). The shortest and longest diameter of the tumor were measured with calipers at the indicated time intervals, and tumor volume (mm 3 ) was calculated using the following standard formula: (the shortest diameter) 2 Â (the longest diameter) Â 0.5. Animals were killed, according to institutional guidelines, when the diameter of their tumors reached 3-4 cm or when significant toxicity was observed.
Animal body weight and any sign of morbidity were monitored. Drug treatment lasted for 29 days, and mice were killed 24 h after the last drug administration. Then, tumors were extirpated, measured and weighed, and a necropsy analysis involving tumors and distinct organs was carried out.
For in vivo analysis of the effect of pravastatin, four cohorts of eight CB17-SCID were assigned, receiving daily oral administration of pravastatin (1.5 mg/kg), edelfosine (30 mg/ kg), pravastatin þ edelfosine or an equal volume of vehicle (water). Pravastatin-treated animals received a 1-week pretreatment of pravastatin. Then, analysis was as above. Cholesterol concentration was determined in isolated tumors using a commercial kit (Calbiochem, San Diego, CA, USA) according to the manufacturer's instructions.
Plasma/tissue extraction procedure for edelfosine biodistribution studies MM-bearing SCID mice were treated with a daily oral administration of edelfosine (30 mg/kg) for 29 days. At 24 h after the last drug oral administration, blood was collected in EDTA surface-coated tubes and then centrifuged at 2000 g for 15 min (4 1C) to collect the plasma (100 ml). Then, the animals were killed and distinct organs and tumors were collected and weighed. Tissues and tumors were homogenized in 1 ml water (pH 7.4) using a Mini-bead Beater (BioSpect Products, Inc, Bartlesville, OK, USA) and centrifuged at 10 000 g for 10 min. Both plasma and tissue supernatants were collected and stored at À80 1C until HPLC-MS analysis was carried out. A 10 mg volume of platelet-activating factor (1 mg/ml), used as internal standard, was added onto 100 ml of plasma or tissue/tumor supernatant. A volume of 190 ml of a mixture of 1% formic acid/methanol was added to precipitate proteins. Samples were vortexed for 1 min and, after centrifugation (20 000 g, 10 min), 25 ml of the supernatant were analyzed by HPLC-MS.
Quantitative determination of edelfosine by HPLC-MS analysis
The technique used was a slight modification of a previously described method (Blanco-Prieto et al., 2004) , and is detailed in the Supplementary data. The range of linear response of this technique was 5-250 ng for plasma samples and 5-685 ng for tissue samples. Edelfosine concentrations (mg/ml and mg/g) were calculated dividing the amount of edelfosine measured in samples by the volume of plasma or the weight of tissue used for the analysis.
Statistical analysis
All values are expressed as means ± s.e. Between-group statistical differences were assessed using Mann-Whitney's test or Student's t-test. A P-value of o0.05 was considered statistically significant. 
